Diese Webseite verwendet Cookies, um Ihnen einen bedarfsgerechteren Service bereitstellen zu können. Indem Sie ohne Veränderungen Ihrer Standard-Browser-Einstellung weiterhin diese Seite besuchen, erklären Sie sich mit unserer Verwendung von Cookies einverstanden. Möchten Sie mehr Informationen zu den von uns verwendeten Cookies erhalten und erfahren, wie Sie den Einsatz unserer Cookies unterbinden können, lesen Sie bitte unsere Cookie Notice.

Bookmark E-Mail Diese Seite drucken

The next phase: Opportunities in China's pharmaceuticals market

The next phase
  • The next phase: Opportunities in China's pharmaceuticals market
  • Life Sciences
  • November 2011
  • 842 KB
  • Download Download (PDF)


As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second-largest LSHC market within this decade.

Organic market growth, driven by a combination of shifting age, wealth, and urbanisation demographics, is a second factor that has whetted the appetite of LSHC players. Many multinational players who have regarded China only as a source of raw materials or research are now contemplating China market entry. Others who have previously entered the market through joint ventures with Chinese companies and research institutes are now ready to ramp up their growth through drug licensing and acquisitions, where the right matches can be found. Key hurdles remain, among them discerning which targets have the desired capabilities, and which present unacceptable risks discoverable only through professional due diligence.

This report focuses in particular on pharmaceuticals companies, both domestic and foreign, and their activities in the China market—all from the viewpoint of prospective investors.

Stay connected
Get connected